Navigation Links
BioMarin to Present at the Jefferies Global Healthcare Conference
Date:5/31/2011

NOVATO, Calif., May 31, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
2. BioMarin Announces First Quarter 2011 Financial Results
3. BioMarin to Present at the Deutsche Bank Healthcare Conference
4. BioMarin to Present at the Barclays Global Healthcare Conference
5. BioMarin to Present at the Cowen Health Care Conference
6. BioMarin to Present at the Citi Global Healthcare Conference
7. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
10. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
11. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... Eugene, OR (PRWEB) , ... September 20, 2017 , ... ... OSHA 10- and 30-Hour and HAZWOPER 8-, 24- and 40-Hour courses from now until ... , In addition to offering these discounted prices to all businesses and government ...
(Date:9/20/2017)... ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A Bible-inspired ... the creation of published author, Bill Miller. Bill Miller has a unique ... than a decade of addiction to prescription drugs. He has a Bachelor ...
Breaking Medicine News(10 mins):